Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.
Open accessThe DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] –0.5% [95% CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD −0.9 kg [95% CI −1.8, −0.0], −2.0 kg [−3.0, −1.0], and −3.3 kg [−4.2, −2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.[2][3][4][5][6]”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationStatistical Analysis with Missing Data
Bo., N., Little, R. J. A., & Rubin, D. B. (1988) · Population (French Edition) · doi:10.2307/1533221 · Cited by 2,095
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 1×
“Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce HbA1c with a low risk of hypoglycemia and favorable effects on body weight (1,2).”
BackgroundSelf-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationStatistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Cited by
Items 201–300 of 319
Ali, A., Siddiqui, A. A., Usman, M., Shahid, I., Khan, M. S., & Perswani, P. (2025) · Clinical Obesity · doi:10.1111/cob.70012 · Cited by 5
Peptide drugs application in metabolic diseases and discovery strategies
Bin, T. E. N. G., Junfeng, L. I., & Ren, P. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00063-8 · Cited by 7
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Delgado, E., Morales, C., Abreu, C., Verdugo, A. A., Carbonell, A. M. P., González, A. C., Valero, J. A. G., López, V. G., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16523 · Cited by 6
“16 To complement these findings, PIONEER REAL, which is a collection of 13 non-interventional studies across Europe, North America, and the Middle East, attempts to understand the implications of these results in real-world settings.”
Targeting the Enteroendocrine System for Treatment of Obesity
Miedzybrodzka, E. L., Gribble, F. M., & Reimann, F. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_583 · Cited by 5
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
Karásek, D. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.018 · Cited by 8
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
Ahmed, M., Hashmi, T. M., Shahzad, M., Zia, R., Ashraf, H., Ahmed, R., Rashid, M. O., Greene, S. J., Mentz, R. J., Fudim, M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag079 · Cited by 4
Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Alsheikh, A., Alshehri, A., ALZAHRANI, S. H., Jammah, A. A., Alqahtani, F., Alotaibi, M. S., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M. S., et al. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100209 · Cited by 4
Wang, T., Cui, Y., & Liao, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01689-1 · Cited by 5
Palazzi, S., Sentinelli, F., Zugaro, A., Morgante, S. N., Santarelli, L., Melanzi, S., Mutiis, A. D., Piersanti, D., Macerola, B., Iezzi, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060856 · Cited by 5
Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020
Chlup, R., Kaňa, R., Hanáčková, L., Zálešáková, H., & Doubravová, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96237 · Cited by 5
Sato, G. E., Uchino, H., & Hirose, T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01631-5 · Cited by 4
“Furthermore, consistent with the results of PIO-NEER 8 [13], we observed a significant reduction in the total daily insulin dose from baseline.”
ResultGLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 5
Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India
Dutta, A., Mahendru, S., Sharma, R., & Mithal, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_266_24 · Cited by 4
Dilatación gástrica aguda asociada al empleo de semaglutida, un análogo de GLP-1
Segura, P. S., Lázaro, Y. A., Tapia, S. M., Puerta, J., & Domingo, J. J. S. (2021) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.11.021 · Cited by 4
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Self-citationSaudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Alromaih, A., Alshamrani, A., Alharbi, B., Alharbi, I., Alharbi, T., Bokhari, S., Elbadawi, H., Almehthel, M. S., Alsaeed, A. H., Alyahia, K., et al. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132017 · Cited by 4
Safety and Efficacy of Semaglutide in Type 2 Diabetes Patients: A Real-World Study
Aneja, P., Bhalla, G., & Jain, A. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_48_24 · Cited by 3
Sanyal, D., Saboo, B., Phatak, S., Kumar, P. K. M., Basu, D., Verma, N., NAIR, A., Bhattacharjee, K., Aneja, P., Makkar, B. M., et al. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_179_25 · Cited by 3
Self-citationGuo, M., Liu, Y., Zeng, Y., Chen, J., Zeng, C., Huang, L., Wang, J. H., Wu, Y., Wu, Q., Teng, F., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70134 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Takahara, M., Shiraiwa, T., Katakami, N., Maeno, Y., Yamamoto, K., Shiraiwa, Y., Yoshida, Y., Kozawa, J., & Shimomura, I. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1441-22 · Cited by 3
“…findings were in line with the smaller HbA1c reduction reported in the trials on oral se-maglutide than in those on injectable semaglu-tide (1, 2, 17, 18), The glucose-lowering effect of oral se-maglutide thus appears to be inferior to that of the corresponding dosage of injectable semaglutide.”
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
Self-citationPostema, A., Gaspersz, J., Baak, B. N., Huisman, E. L., Hoogstraten, C., Hagelund, L. M., Beest, F. J. A. P., & Overbeek, J. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70251 · Cited by 2
Garma, J. L., Mouce, C. G., Novo, N. R., Trastoy, O. D., Nieto, A. S., Castro, P. P., Díaz-Ortega, C., Fernández-Rodríguez, E., Carballeira, R. P., Pinal-Osorio, I., et al. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501713 · Cited by 3
Prasad, A., Arora, A., Arora, A., Vaid, J., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70515 · Cited by 3
Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports
Alorfi, N. M., Alourfi, M. M., AlDabbagh, A., Alghamdi, W., Ghamdi, S. S. A., Aldekhail, N. M., Alkhanani, M., Alansari, A. M., Alsolami, F. A., & Ibrahim, N. A. (2026) · Medicine · doi:10.1097/md.0000000000048811 · Cited by 2
“[9,10] [11–13] Gastrointestinal adverse events such as nausea, vomiting, and diarrhea are the most frequently reported treatment-limiting reactions and are well recognized as class effects of GLP-1 receptor agonists.”
Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
Escobar, C., Castro, A., Cerezo, J. F. G., Górriz, J. L., Obaya, J. C., & Villar‐Taibo, R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00013-9 · Cited by 7
Mohanan, P. P., & Jariwala, P. V. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.010 · Cited by 2
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Wollenhaupt, D., Wolters, J., Aziz, M. S. A. E., & Nauck, M. A. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003296 · Cited by 2
Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
Self-citationAre the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
Xie, S., Ye, L., Yang, A., Li, X., & Yin, Y. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2618-7509 · Cited by 2
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Brodosi, L., Musio, A., Barbanti, F. A., Mita, D., Marchesini, G., & Petroni, M. L. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.88 · Cited by 2
Using Forced Degradation to Aid the Development of Biopharmaceutical Products
Benet, A. (2021) · Deep Blue (University of Michigan) · doi:10.7302/2763 · Cited by 2
Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist
Mohan, B. P., & Eligar, V. S. (2021) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410146 · Cited by 1
Real-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study
Chittawar, S., Suri, S., Garg, A., Gupta, V., Patni, B., Mitra, A., Handral, A., Desai, A., Aggarwal, R., & Goyal, R. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_31_24 · Cited by 1
Ohara, M., Yokoyama, H., Seino, H., Fujikawa, T., Kohata, Y., Takahashi, N., Irie, S., Terasaki, M., Mori, Y., Fukui, T., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01691-y · Cited by 1
“Moreover, a Phase III clinical trial of oral semaglutide demonstrated signi�cant improvement in self-monitored postprandial glucose levels compared to placebo at 26 weeks [33, 39].”
Wang, J., Xie, T., Zhang, Y., & Zhang, H. (2025) · Cardiorenal Medicine · doi:10.1159/000546238 · Cited by 2
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Kempf, K., Röhling, M., & Martin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1644442 · Cited by 1
Seighali, N., Chahkand, M. S. G., Ebrahimzade, M., Arashlow, F. T., Maroufi, S. P., Rahnama, P., Matin, M. H., Javazm, A. K., Ebrahimi, P., Nasir, K., et al. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01149-5 · Cited by 2
“Ten studies were judged to be at low risk of bias [25, 27, 28, 30–36].”
Malighetti, M. E., Vescini, F., Carpentieri, M. S., Altomari, A., Turchi, F., Porto, A. D., & Dauriz, M. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04376-3 · Cited by 1
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Giaccari, A., Borroni, F., Dauriz, M., Gioia, D., Baptiste, P. J., Bisio, A., Lastoria, G., Udupa, K., & Barbagallo, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113244 · Cited by 1
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Vadén, A., Lahelma, M., NURMI, L., Heikkilä, E., Vessari, H., Luoto, H., Saukkonen, T. T., & Niskanen, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70920 · Cited by 1
“Similarly, clinical trials have shown smaller reductions by 12 months, ranging from 2.6 to 4.4 kg [1, 17, 18].”
InfluentialOrtiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Zhong, Y., Tan, X., Zhang, L., & Wu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1916932 · Cited by 1
“…et al., 2025; Mahaffey et al., 2025; Marso et al., 2016; McGuire et al., 2025; Mosenzon et al., 2019; Mu et al., 2024; Perkovic et al., 2024; Pratley et al., 2019; Rodbard et al., 2018; Sorli et al., 2017; Warren et al., 2018; Yamada et al., 2020; Zinman et al., 2019a; Zinman et al., 2019b).”
Larger, É. (2021) · médecine/sciences · doi:10.1051/medsci/2020261 · Cited by 2
Yoneda, C., Kobayashi, J., & Kuribayashi, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00734-5 · Cited by 1
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Kahol, R., Jain, A., Sharma, N., & Mishra, S. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1950 · Cited by 1
Los arGLP1: una oportunidad para el tratamiento del riesgo cardiometabólico
Miramontes‐González, J. P. (2021) · doi:10.52102/contexto_epidemiologico/art-3
Studying the interactions of IT/IS and human resource management in multicultural societies.
Siakas, K. V., & Georgiadou, E. (2003)
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3
Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1
A semaglutida oral irá substituir a cirurgia metabólica? Revisão sistemática
Guimarães, A. P. S. E. S., Sendin, A. L., & Campolina, C. D. O. C. (2022) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv3n2-009 · Cited by 1
Semaglutide: A Strategic Weapon for Primary Care
Jain, A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u3
Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist
Soubry, E., Mathieu, C., Vandistel, G., & Mertens, A. C. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.068
A korai erélyes glikémiás kontroll jelentősége 2-es típusú cukorbetegségben
Hosszúfalusi, N. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.s1.2
Beneficios cardiovasculares del semaglutide: un nuevo agonista del GLP-1
Ortega, J. P. G., Ramón, S. M. Q., Panamá, J. C. P., Cajas, J. I. P., Pineda, E. G. R., Sacoto, E. P. L., Masache, G. A. R., Delgado, A. M. G., Calle, M. E. R., & Quizhpi, P. F. B. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7702783
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
Viliušytė, M., Maleckas, A., & Malinauskas, M. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.021
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000021
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.23000052
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Semaglutide in the Treatment of Diabetes and Associated Obesity
Makuch, R., Chrościcka, A., Gała, K., Czajka, A., Lenard, P., Kucharski, A., Michalska, S., Pilarski, K., Dewicka, M., & Wawrzyniak, A. M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.73.51699
“…impaired kidney function (PIONEER 5), the possibility of reducing the average daily insulin dose when used together with semaglutide (PIONEER 8), and higher effectiveness in lowering HbA1c with oral semaglutide at a dose of 14mg compared to Dulaglutide at a dose of 0.9 mg (PIONEER 10) [23,24,25].”
InfluentialThe efficacy of oral semaglutide in weight loss and glycemic control
Lopes, C. A., Lima, L. D. S., Eccard, J. V. A. A., & Gama, L. L. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594552414069
Diabetes tipo 2: contexto fisiopatológico e atualização terapêutica com o uso da semaglutida
de Paula, W. G., Pacheco, R. B., Neves, C. O. N., & Ligório, G. T. (2024) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e16285.2024 · Cited by 1
Makowska, K., Billewicz, M., Marczyk, A., & Lis, L. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.54194
“In patients with more advanced T2D on basal insulin (PIONEER 8), semaglutide addition resulted in substantial HbA1c reductions compared to placebo at both 26 and 52 weeks [20] .”
BackgroundSind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Advancing Type 2 Diabetes Management with Semaglutide: Clinical and Real-World Insights
Srivastava, M., Ampeti, S., Sonam Shashikala, B., V, Sheikh, R. B., Kirankumar, P. N., & Sali, S. R. (2025) · medtigo Journal of Medicine · doi:10.63096/medtigo3061238
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Ormanac, K., Božek, T., Žuljević, K., Grbavac, J., Petrinović, M., Majanović, S. K., Canecki-Varžić, S., Berković, M. C., & Bilić-Čurčić, I. (2025) · Diabetology · doi:10.3390/diabetology6110127
EFEITOS NEUROMETABÓLICOS DOS AGONISTAS DE GLP-1
Dino, K. Ó., Miranda, S. C. D., Freitas, R. M. D., Nascimento, I. A. D. C., Pires, D. T., & Lopes, G. F. A. (2025) · REVISTA ERR01 · doi:10.56238/err01v10n6-010
Garma, J. L., Mouce, C. G., Novo, N. R., Trastoy, O. D., Nieto, A. S., Castro, P. P., Ortega, C. D., Rodríguez, E. F., Carballeira, R. P., Osorio, I. P., et al. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501713
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Self-citationHusain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Self-citationWannachalee, T., Anthanont, P., Sirisreetreerux, S., Nayak, G., Chumchujan, W., Iamsudjai, Y., & Buranapin, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70701
“Oral semaglutide has demonstrated superior glycaemic and weight reductions versus placebo and standard oral therapies in a recently published clinical trial, achieving HbA1c reductions up to 1.2% with a low risk of hypoglycaemia due to its glucose-dependent mechanism [15].”
InfluentialGonzález-Gálvez, G., Garnica-Cuéllar, J. C., Colín‐García, M. Á., Ferreira‐Hermosillo, A., Jimenez-Ramos, S. A., Contreras-Sandoval, A. Y., Cruz-Puente, P., & Duarte-Vega, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70219
“These findings align with the PIONEER phase 3a trial (Supplementary Table 1) [6–13] and a pooled analysis of seven country-specific PIONEER REAL studies from Canada, Denmark, Italy, the Netherlands, Sweden, Switzerland, and the UK [16].”
Influential
Metadata
- Authors
- Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J.-F., Serusclat, P., Cariou, B., Gourdy, P., Fradet, G., Monier, A., Borot, S., Monguillon, P., Gouet, D., Doupis, J., Tentolouris, N., Tsimichodimos, V., Melidonis, A., Bekiari, E., Bargiota, A., Agarwal, S., Saboo, B., Chatterjee, S., Mohan, V., Shaikh, S., Gupta, Y., Bhattacharyya, A., Manikath, N., Jain, S., Sasaki, T., Osonoi, T., Fukuda, S., Wada, S., Kiyosue, A., Ide, Y., Onishi, Y., Matoba, K., Takai, K., Yamauchi, A., Inoue, S., Kaneko, S., Ikeda, H., Ohta, Y., Hisatomi, A., Senokuchi, T., Jinnouchi, H., Nakamura, S., Soto, J. R. L., Briones, I. R., Bogdanski, P., Szyprowska, E., Modzelewska, A., Wozniak, I., Zyangirova, S., Sergeeva-Kondrachenko, M., Davis, T., Thomson, S., Frias, J., Gandy, W., Lingvay, I., Pounds, K., Bowman-Stroud, C., Dempsey, M., Huffman, D., Ahmed, A., Fraser, N., Ortiz-Carrasquillo, R., Bolster, D. E., Adams, M., Hummel, M., Free, A., Houser, P., Shockey, G., Barnum, O., Bhasker, K., Cornett, G., Streja, D., Kirby, W., Lynd, S., Folkerth, S., Nakhle, S., Norwood, P., Perez, R., Snyder, B., Farris, N., Litchfield, W., Hamdy, O., Park, J., Aroda, V., & Buse, J.
- Affiliations
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- University of North Carolina at Chapel Hill (US)
- Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Kumamoto University (JP)
- ORCID
- Aroda, Vanita R.
- Buse, John B.
- Harris, Stewart B.
- Araki, Eiichi
- Bajaj, Harpreet
- Woo, Vincent
- Gourdy, Pierre
- Borot, Sophie
- Bekiari, Eleni
- Saboo, Banshi
- Chatterjee, Sanjay
- Mohan, Viswanathan
- Shaikh, Shehla
- Gupta, Yashdeep
- Bhattacharyya, Arpandev
- Sasaki, Takashi
- Osonoi, Takeshi
- Kiyosue, Arihiro
- Onishi, Yukiko
- Kaneko, Shizuka
- Ikeda, Hiroki
- Ohta, Yasuharu
- Senokuchi, Takafumi
- Jinnouchi, Hideaki
- Nakamura, Shuji
- Lingvay, Ildiko
- Norwood, Paul
- Hamdy, Osama
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-07-10
- Volume
- 42
- Issue
- 12
- Pages
- 2262-2271
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7364672
- OpenAlex
- W2974714926
- Semantic Scholar
- dfcdee292cee0de5fee471e8d85a78bf385a1d29
- Cited by
- 300
- References
- 37
- Citations by year
- 2026: 28 · 2025: 62 · 2024: 51 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 41 · 2019: 3
- FWCI
- 25.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- MannKind Corporation
- Kowa Company
- Zafgen
- Boehringer Ingelheim Japan
- Eisai
- Novo Nordisk (U54-DK-118612, UC4-DK-108612, UL1-TR-002489)
- Astellas Pharma
- Shionogi
- Terumo
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- National Institutes of Health (UL1TR002489, UL1-TR-)
- Japan Society for the Promotion of Science (17H04201, 18K08482)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK108612, U01DK098246, U54DK118612)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, insulin, metformin, glycemic control, HbA1c, weight loss, nausea, GLP-1 receptor agonists, treatment policy estimand, dose-dependent effects, uncontrolled diabetes, adverse events, tolerability, rescue medication, treatment discontinuation
- MeSH terms
- Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Nausea, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.